[Plasma methotrexate concentrations in urothelial cancer chemotherapy].
The plasma methotrexate (MTX) concentration was measured during 50 courses of chemotherapy on 26 urothelial cancer patients. A dose of 300 mg/body MTX was infused within 2 hours and plasma concentrations were measured at the scheduled times. Plasma level at the end of infusion was (2.3 +/- 0.8) x 10(-5) M/L, (2.9 +/- 1.9) x 10(-5) M/L at the 6th-hour, and (1.9 +/- 1.8) x 10(-7) M/L at the 24th-hour after the infusion. The plasma MTX concentration values were inversely correlated with creatinin clearance. In 6 cases of Kock pouch bladder, clean intermittent self catheterization of urine caused no meaningful increase of MTX.
Kitamura
Y
Y
Department of Urology, Niigata Cancer Center Hospital.
Watanabe
M
M
Komatsubara
S
S
Sakata
Y
Y
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000097:blood* / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood* / Q000188:drug therapy; D007682:Kidney Pelvis; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000097:blood*; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000097:blood* / Q000188:drug therapy
D005047:Etoposide; D002945:Cisplatin; D008727:Methotrexate